Midlife weight gain rarely responds to the same strategies that worked in your 30s. Your changing hormones and metabolism alter everything from where your body stores fat to how well you sleep. In fact, these internal shifts explain why traditional diet and exercise plans suddenly stop working in your 40s.

When lifestyle changes fail to deliver results, modern medical treatments can help you regain control. Medications like GLP-1s for perimenopause directly target menopause-related metabolic changes. Early research shows these drugs are just as powerful in this life stage, and combining them with hormone replacement therapy (HRT) may make them even more effective. This article breaks down how GLP-1 medications work, why pairing them with HRT improves results, and how to choose the right treatment path for you. 

Why does perimenopause weight gain happen?

Several factors cause perimenopause weight gain. This midlife transition triggers specific hormonal and physical changes that alter how your body burns energy and stores fat. 

Declining estrogen levels

Normally, estrogen keeps your cells sensitive to insulin so your body can easily use blood sugar for energy. At the same time, the hormone directs normal fat storage to your hips and thighs. As estrogen declines, your cells resist insulin. To compensate, your body pumps out more insulin, which signals your system to store fat instead of burning it. Your body deposits this new fat around your abdomen, where it releases inflammatory signals that further worsen insulin resistance. 

Accelerated muscle loss

Plunging estrogen levels deactivate the stem cells your body uses to repair and rebuild muscle tissue. Without this hormonal signal, muscle breakdown outpaces muscle growth, shrinking lean muscle mass and dropping your resting metabolic rate. Because lean tissue burns more calories at rest than fat, this loss drops the amount of fuel your body needs for daily activities. In turn, your body stores away those unspent calories as fat.

Disrupted sleep

Frequent night sweats and hot flashes disrupt your sleep cycle. Chronic sleep deprivation forces your hormonal system to overproduce the hunger hormone (ghrelin) while suppressing the fullness hormone (leptin). This creates a chemical imbalance that drives up daytime cravings and slows down your metabolism.

Elevated stress

Chronic midlife stress triggers your adrenal glands to release the stress hormone cortisol. This constant stream of cortisol binds to receptors in abdominal tissue. Once bound, the hormone activates fat-storing enzymes. Instead of depositing normal under-the-skin (subcutaneous) fat, these enzymes pack on deep visceral belly fat. This internal fat wraps around your vital organs, releasing inflammatory proteins that damage blood vessels and increase your risk for heart disease and type 2 diabetes.

What are GLP-1s, and how do they help in perimenopause?

Your gut naturally produces glucagon-like peptide-1 (GLP-1). This hormone manages your appetite by signaling fullness to your brain and slowing down how fast your stomach empties. At the same time, it stabilizes your blood sugar by prompting your pancreas to release insulin when you eat. It also stops your liver from dumping extra sugar into your bloodstream between meals. 

GLP-1s are medications that mimic these effects at a much higher intensity. This medication category includes weekly injectables and daily oral pills:

• Semaglutide (Wegovy^®, Ozempic^®)
• Tirzepatide (Zepbound^®, Mounjaro^®) 
• Orforglipron (Foundayo^®)

The FDA approves these specific brands for different uses: Wegovy^®, Zepbound^®, and Foundayo^® for weight management, and Ozempic^® and Mounjaro^® for type 2 diabetes.

These medications don’t replace falling estrogen or treat hot flashes. Instead, they target your metabolism, balancing out the insulin resistance, appetite changes, and abdominal fat storage that drive weight up. 

Does GLP-1 help with perimenopause weight gain? 

A 2025 analysis of the SURMOUNT trial studied how these medications perform across different reproductive stages. The data proved the high effectiveness of tirzepatide in perimenopause. 

Women taking tirzepatide achieved substantial weight loss regardless of their menopausal stage, dropping up to 26% of their total body weight. Furthermore, their waist circumference fell by an average of 20–22 centimeters across all groups, proving that the medication directly targets stubborn abdominal fat. Researchers observed similar results for all GLP-1s approved for weight loss.

GLP-1 and HRT together: Is the combination more effective?

GLP-1 medications and HRT treatment address entirely different pieces of the perimenopause weight loss puzzle. GLP-1s manage the effects of hormonal changes like intense cravings, insulin resistance, and visceral belly fat storage. HRT treats the problem at its root by stabilizing your dropping estrogen (and sometimes progesterone) levels. 

Recent clinical data reveals that pairing HRT with GLP-1 medications helps them work at their highest potential, delivering maximum metabolic support. When used together, they deliver these benefits:

• Greater and faster weight loss: A 2024 Mayo Clinic study found that after one year on semaglutide, women also taking HRT lost an average of 16% of their body weight, compared to just 12% for those taking the weight loss drug alone. A 2026 follow-up study showed a similar boost for tirzepatide, where women pairing the drug with HRT achieved a 19% weight reduction compared to 14% for those taking the medication alone.
• Higher success rates: Combining these treatments increases your likelihood of hitting clinically significant weight loss milestones. In the same Mayo Clinic trial, 100% of the women combining semaglutide and HRT successfully reached the 5% weight loss target, while only 77% of the women on semaglutide alone reached that same goal.
• Enhanced cardiovascular health: The compound benefits of dual therapy extend beyond the scale. While both patient groups see major improvements in blood sugar control, women adding HRT to their regimen achieve sharper drops in blood pressure, harmful blood fats (triglycerides), and liver inflammation.

What to consider before starting a GLP-1 in perimenopause

These are a few key factors to consider when deciding if GLP-1 is the right choice to manage your perimenopause weight gain:

• Body weight: The FDA approves GLP-1 medications primarily for individuals with a body mass index (BMI) of 30 or above, or a BMI of 27 or above alongside a weight-related health condition like high blood pressure or prediabetes.
• Abdominal fat accumulation: Healthcare providers frequently prescribe these medications when a woman develops an expanding waistline despite maintaining a consistent diet and exercise routine. This is a common issue during midlife, as dropping hormones naturally reroute fat storage toward the abdomen.
• Lean body composition protection: GLP-1 medications deplete lean muscle mass alongside body fat. In the SURMOUNT clinical trials, lean mass accounted for about 25% of the weight lost on tirzepatide. Because perimenopause already speeds up muscle loss, your provider will likely prescribe a high-protein diet and dedicated resistance training alongside your medication to protect your existing muscle. 
• Medical contraindications: Certain preexisting health conditions rule out GLP-1 therapy entirely. For safety, you can’t take these medications if you have a personal or family history of medullary thyroid carcinoma (MTC), a rare form of thyroid cancer. You also can’t take them if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), a genetic condition that causes hormone-producing tumors.

A GLP-1 medication works best as one tool within a broader midlife care plan. Your healthcare provider can help you design a customized strategy that supports your body and long-term health goals.

Maven Clinic can help you find the right approach for your body

GLP-1 medications target some metabolic shifts that drive perimenopause weight gain. Adding HRT can help address the hormonal root cause. Successfully balancing both treatments requires a provider who understands how these therapies interact in a changing body.

Maven Clinic’s GLP-1 Care program connects you with board-certified physicians who specialize in women’s metabolic and hormonal health. Your monthly membership simplifies your care by covering dose adjustments alongside two monthly specialist consultations for nutrition guidance and strength training support. If HRT is part of your treatment, your care team can help you coordinate both therapies under one plan. 

Take control of your health today. Log into your Maven account to see if your insurance covers the cost of your care and medications.

FAQ

Are GLP-1 medications approved for perimenopause weight gain?

The FDA hasn’t approved any GLP-1 medications specifically for perimenopause. However, the agency has approved several of these drugs for general weight management. Perimenopause weight gain frequently pushes women past the FDA approval thresholds: a BMI of 30 or above, or a BMI of 27 or above alongside a weight-related health condition like high blood pressure or prediabetes. 

Should I start HRT before using a GLP-1 medication in perimenopause?

You don’t need to take HRT before starting a GLP-1 medication for weight loss. However, if you actively experience severe hot flashes or night sweats, stabilizing those symptoms (and your hormones) with HRT first can set your body up to respond better to GLP-1 therapy.

Severe hot flashes and an interrupted sleep schedule during perimenopause trigger a surge of the stress hormone cortisol. Your brain interprets this physical stress as a crisis and forces your body into survival mode. To save quick energy, your body stores fat in your abdomen and signals your liver to dump extra sugar into your bloodstream. HRT lowers cortisol, calming this survival response. This creates a more receptive environment for the GLP-1 medication to do its job.